The aminopeptidase inhibitor CHR-2863 is an orally bioavailable inhibitor of murine malaria

Tina S. Skinner-Adams; Christopher L. Peatey; Karen Anderson; Katharine R. Trenholme; David Krige; Christopher L. Brown; Colin Stack; Desire M.M. Nsangou; Rency T. Mathews; Karine Thivierge; John P. Dalton; Donald L. Gardiner

doi:10.1128/AAC.06245-11

The aminopeptidase inhibitor CHR-2863 is an orally bioavailable inhibitor of murine malaria

Tina S. Skinner-Adams
, Christopher L. Peatey
, Karen Anderson
, Katharine R. Trenholme
, David Krige
, Christopher L. Brown
, Colin Stack
, Desire M.M. Nsangou
, Rency T. Mathews
, Karine Thivierge
, John P. Dalton
, Donald L. Gardiner

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

41 Citations (Scopus)

Abstract

Malaria remains a significant risk in many areas of the world, with resistance to the current antimalarial pharmacopeia an everincreasing problem. The M1 alanine aminopeptidase (PfM1AAP) and M17 leucine aminopeptidase (PfM17LAP) are believed to play a role in the terminal stages of digestion of host hemoglobin and thereby generate a pool of free amino acids that are essential for parasite growth and development. Here, we show that an orally bioavailable aminopeptidase inhibitor, CHR-2863, is efficacious against murine malaria.

Original language	English
Pages (from-to)	3244-3249
Number of pages	6
Journal	Antimicrobial Agents and Chemotherapy
Volume	56
Issue number	6
DOIs	https://doi.org/10.1128/AAC.06245-11
Publication status	Published - Jun 2012
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1128/AAC.06245-11

Cite this

Skinner-Adams, T. S., Peatey, C. L., Anderson, K., Trenholme, K. R., Krige, D., Brown, C. L., Stack, C., Nsangou, D. M. M., Mathews, R. T., Thivierge, K., Dalton, J. P., & Gardiner, D. L. (2012). The aminopeptidase inhibitor CHR-2863 is an orally bioavailable inhibitor of murine malaria. Antimicrobial Agents and Chemotherapy, 56(6), 3244-3249. https://doi.org/10.1128/AAC.06245-11

@article{55d4163651434350b0bc72678db15008,

title = "The aminopeptidase inhibitor CHR-2863 is an orally bioavailable inhibitor of murine malaria",

abstract = "Malaria remains a significant risk in many areas of the world, with resistance to the current antimalarial pharmacopeia an everincreasing problem. The M1 alanine aminopeptidase (PfM1AAP) and M17 leucine aminopeptidase (PfM17LAP) are believed to play a role in the terminal stages of digestion of host hemoglobin and thereby generate a pool of free amino acids that are essential for parasite growth and development. Here, we show that an orally bioavailable aminopeptidase inhibitor, CHR-2863, is efficacious against murine malaria.",

author = "Skinner-Adams, \{Tina S.\} and Peatey, \{Christopher L.\} and Karen Anderson and Trenholme, \{Katharine R.\} and David Krige and Brown, \{Christopher L.\} and Colin Stack and Nsangou, \{Desire M.M.\} and Mathews, \{Rency T.\} and Karine Thivierge and Dalton, \{John P.\} and Gardiner, \{Donald L.\}",

year = "2012",

month = jun,

doi = "10.1128/AAC.06245-11",

language = "English",

volume = "56",

pages = "3244--3249",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "6",

}

TY - JOUR

T1 - The aminopeptidase inhibitor CHR-2863 is an orally bioavailable inhibitor of murine malaria

AU - Skinner-Adams, Tina S.

AU - Peatey, Christopher L.

AU - Anderson, Karen

AU - Trenholme, Katharine R.

AU - Krige, David

AU - Brown, Christopher L.

AU - Stack, Colin

AU - Nsangou, Desire M.M.

AU - Mathews, Rency T.

AU - Thivierge, Karine

AU - Dalton, John P.

AU - Gardiner, Donald L.

PY - 2012/6

Y1 - 2012/6

N2 - Malaria remains a significant risk in many areas of the world, with resistance to the current antimalarial pharmacopeia an everincreasing problem. The M1 alanine aminopeptidase (PfM1AAP) and M17 leucine aminopeptidase (PfM17LAP) are believed to play a role in the terminal stages of digestion of host hemoglobin and thereby generate a pool of free amino acids that are essential for parasite growth and development. Here, we show that an orally bioavailable aminopeptidase inhibitor, CHR-2863, is efficacious against murine malaria.

AB - Malaria remains a significant risk in many areas of the world, with resistance to the current antimalarial pharmacopeia an everincreasing problem. The M1 alanine aminopeptidase (PfM1AAP) and M17 leucine aminopeptidase (PfM17LAP) are believed to play a role in the terminal stages of digestion of host hemoglobin and thereby generate a pool of free amino acids that are essential for parasite growth and development. Here, we show that an orally bioavailable aminopeptidase inhibitor, CHR-2863, is efficacious against murine malaria.

UR - https://www.scopus.com/pages/publications/84861161965

U2 - 10.1128/AAC.06245-11

DO - 10.1128/AAC.06245-11

M3 - Article

C2 - 22450967

AN - SCOPUS:84861161965

SN - 0066-4804

VL - 56

SP - 3244

EP - 3249

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 6

ER -

The aminopeptidase inhibitor CHR-2863 is an orally bioavailable inhibitor of murine malaria

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this